Cost effectiveness of fractional doses of COVID-19 vaccine boosters in India.

ABSTRACT:

Background

Coronavirus disease 2019 (COVID-19) continues to be a major global public health crisis that exacts significant human and economic costs. Booster vaccination of individuals can improve waning immunity and reduce the impact of community epidemics.

Methods

Using an epidemiological model that incorporates population-level severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and waning of vaccine-derived immunity, we identify the hypothetical potential of mass vaccination with fractionated vaccine doses specific to ChAdOx1 nCoV-19 (AZD1222 [Covishield]; AstraZeneca) as an optimal and cost-effective strategy in India's Omicron outbreak.

Findings

We find that the optimal strategy is 1/8 fractional dosing under mild (Re ∼ 1.2) and rapid (Re ∼

SUBMITTER: Du Z 

PROVIDER: S-EPMC9922587 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature